RELATIONSHIP BETWEEN TROPISM, INFECTIVITY, AND NEUTRALIZATION IN HIV
HIV 的趋向性、感染性和中和作用之间的关系
基本信息
- 批准号:2568928
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
While all the determinants of tropism of HIV replication are still being
elucidated, the major determinants reside in the envelope of the virus
and are present in both the extracellular (gp120) and the transmembrane
(gp41) components. However, other genes (gag, nef, vpr, vif) and
cis-acting elements (the long terminal repeat, LTR, the primer binding
site, PBS, and the polypurine tract, PPT) may also modulate replication
in different cell types. Our previous work has involved characterizing
determinants of tropism that reside in the envelope gene. The approach
involves passaging a virus with reduced replication capacity on cells in
which that reduced replication ability is manifested. Because of the
high propensity of HIV to mutate, the emergence of variants with
increased replication capacity is frequently seen. The type and location
of mutations that account for the observed phenotype have been
informative in delineating those genes or regions of the HIV genome
invloved in the particular function. Recently, we have applied this
approach to the study of the primer binding site (PBS) and the polypurine
tract (PPT) of the ROD strain HIV-2. While most HIV-1 and HIV-2 strains
use the host tRNA Lys3 species as primer for the minus-strand cDNA
synthesis, the ROD10 clone of HIV-2 carries a sequence change in the PBS
that results in a different tRNA being incorporated. This tRNA
corresponds to a tRNA species that we refer to as tRNA Lys7. The
question of whether tRNA Lys7 is used for HIV-2 ROD10 replication and
whether the non-canonical PBS is maintained during passage was addressed
by sequencing the PBS after passaging in PBMC and T-cell lines. There
was rapid conversion to the canonical PBS after even a single passage in
either PBMC or cell lines. After two passages, the proportion of the PBS
corresponding to the Lys7 tRNA was about 30 to 50%. Further passages are
underway to determine if the non-canonical PBS reverts completely. In
addition, since there are determinants other than the PBS for
incorporation of the appropriate tRNA, we are constructing hybrid viruses
between ROD10 and ROD2, another isolate of HIV-2 ROD that has the
canonical PBS and uses tRNA Lys3 as primer, in order to identify and map
these other determinants. HIV-2 ROD has another unusual feature. The
PPT is not the usual all-purine canonical element of the majority of
retroviruses but has a PPT that is interrupted with a pyrimidine residue.
Since this virus is infectious, we sequenced the PPT from passaged virus
and found that the non-canonical PPT was retained on culture.
Furthermore, that there are three clones of ROD and all three have this
PPT demonstrates that this PPT exists in vivo, that it is fully
functional, and that it is selected for. Future studies will assess the
interaction between the PPT and RT/RNaseH by replacing the ROD PPT with
a canonical PPT and measuring the stability of this PPT.
虽然所有决定HIV复制趋向性的因素仍在研究中,
阐明,主要决定因素驻留在病毒的包膜
并且存在于细胞外(gp 120)和跨膜
(gp 41)组分。 然而,其他基因(gag,nef,vpr,vif)和
顺式作用元件(长末端重复序列,LTR,引物结合位点,
位点,PBS和多嘌呤段,PPT)也可以调节复制
在不同的细胞类型。 我们之前的工作包括描述
存在于包膜基因中的向性决定因素。 的方法
包括将复制能力降低的病毒在细胞上传代,
这表明复制能力降低。 因为
艾滋病毒变异的高倾向,变异的出现,
经常看到复制容量增加。 类型和位置
解释观察到的表型的突变已经被
在描述HIV基因组的那些基因或区域方面提供信息
在特定的功能中。 最近,我们应用了
引物结合位点(PBS)和多嘌呤的研究方法
图1示出了ROD株HIV-2的病毒片段(PPT)。 虽然大多数HIV-1和HIV-2病毒株
使用宿主tRNA Lys 3种类作为负链cDNA的引物
合成时,HIV-2的ROD 10克隆在PBS中携带序列变化
导致不同的tRNA被整合。 该tRNA
对应于一种我们称之为tRNA Lys 7的tRNA。 的
tRNA Lys 7是否用于HIV-2 ROD 10复制的问题,
在传代期间是否维持非标准PBS,
通过在PBMC和T细胞系中传代后对PBS进行测序。 那里
即使是单次传代后,
PBMC或细胞系。 两次传代后,PBS的比例
对应于Lys 7 tRNA的表达量约为30 - 50%。 其他通道是
正在进行中,以确定非典型的PBS是否完全恢复。 在
此外,由于除了PBS之外还有其他决定因素,
掺入适当的tRNA,我们正在构建杂交病毒,
在ROD 10和ROD 2之间,另一种HIV-2 ROD分离株具有
以tRNALys 3为引物,进行鉴定和定位
这些其他的决定因素。 HIV-2 ROD还有另一个不寻常的特征。 的
PPT并不是大多数人通常的全嘌呤典型元素,
逆转录病毒,但具有被嘧啶残基中断的PPT。
由于该病毒具有感染性,我们对传代病毒的PPT进行了测序
并发现非规范PPT保留在培养物上。
此外,有三个克隆的ROD和所有三个有这个
PPT表明,这种PPT存在于体内,它是完全
功能性的,它被选中。 未来的研究将评估
PPT和RT/RNaseH之间的相互作用,将ROD PPT替换为
一个典型的PPT并测量该PPT的稳定性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
K PEDEN其他文献
K PEDEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('K PEDEN', 18)}}的其他基金
USE OF ACCESSORY GENE MUTANTS FOR THE DEVELOPMENT OF ATTENUATED HIV VACCINES
使用辅助基因突变体开发减毒 HIV 疫苗
- 批准号:
3748153 - 财政年份:
- 资助金额:
-- - 项目类别:
USE OF ACCESSORY GENE MUTANTS FOR THE DEVELOPMENT OF ATTENUATED HIV VACCINES
使用辅助基因突变体开发减毒 HIV 疫苗
- 批准号:
5200718 - 财政年份:
- 资助金额:
-- - 项目类别:
USE OF ACCESSORY GENE MUTANTS FOR THE DEVELOPMENT OF ATTENUATED HIV VACCINES
使用辅助基因突变体开发减毒 HIV 疫苗
- 批准号:
6161247 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF MOLECULAR BIOLOGICAL METHODS TO VACCINE AND CELL SUBSTRATE SAFETY
疫苗和细胞基质安全的分子生物学方法的开发
- 批准号:
6161253 - 财政年份:
- 资助金额:
-- - 项目类别:
A GENETIC AND BIOLOGICAL ANALYSIS OF HIV-1 AND HIV-2
HIV-1 和 HIV-2 的遗传和生物学分析
- 批准号:
3768914 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF MOLECULAR BIOLOGICAL METHODS TO VACCINE AND CELL SUBSTRATE SAFETY
疫苗和细胞基质安全的分子生物学方法的开发
- 批准号:
6101188 - 财政年份:
- 资助金额:
-- - 项目类别:
RELATIONSHIP BETWEEN TROPISM, INFECTIVITY, AND NEUTRALIZATION IN HIV
HIV 的趋向性、感染性和中和作用之间的关系
- 批准号:
6161248 - 财政年份:
- 资助金额:
-- - 项目类别:
USE OF ACCESSORY GENE MUTANTS FOR THE DEVELOPMENT OF ATTENUATED HIV VACCINES
使用辅助基因突变体开发减毒 HIV 疫苗
- 批准号:
2568927 - 财政年份:
- 资助金额:
-- - 项目类别:
RELATIONSHIP BETWEEN TROPISM, INFECTIVITY, AND NEUTRALIZATION IN HIV
HIV 的趋向性、感染性和中和作用之间的关系
- 批准号:
6101183 - 财政年份:
- 资助金额:
-- - 项目类别:














{{item.name}}会员




